>
Switch to:

# Corcept Therapeutics ROC %

: 110.87% (As of Dec. 2020)
View and export this data going back to 2004. Start your Free Trial

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Corcept Therapeutics's annualized return on capital (ROC %) for the quarter that ended in Dec. 2020 was 110.87%.

As of today (2021-04-12), Corcept Therapeutics's WACC % is 4.87%. Corcept Therapeutics's ROC % is 107.29% (calculated using TTM income statement data). Corcept Therapeutics generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.

## Corcept Therapeutics ROC % Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.

 Corcept Therapeutics Annual Data Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 ROC % 48.96 194.01 75.67 89.38 92.09

 Corcept Therapeutics Quarterly Data Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 ROC % 97.78 101.37 124.73 114.44 110.87

## Corcept Therapeutics ROC % Calculation

Corcept Therapeutics's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2020 is calculated as:

 ROC % (A: Dec. 2020 ) = NOPAT / Average Invested Capital = Operating Income * ( 1 - Tax Rate % ) / ( (Invested Capital (A: Dec. 2019 ) + Invested Capital (A: Dec. 2020 )) / count ) = 128.202 * ( 1 - 19.45% ) / ( (118.843 + 105.424) / 2 ) = 103.266711 / 112.1335 = 92.09 %

where

 Invested Capital (A: Dec. 2019 ) = Total Assets - Accounts Payable & Accrued Expense - Excess Cash = Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets + Cash, Cash Equivalents, Marketable Securities )) = 412.312 - 24.952 - ( 275.962 - max(0, 38.841 - 307.358 + 275.962 )) = 118.843

 Invested Capital (A: Dec. 2020 ) = Total Assets - Accounts Payable & Accrued Expense - Excess Cash = Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets + Cash, Cash Equivalents, Marketable Securities )) = 571.731 - 35.3 - ( 440.696 - max(0, 47.494 - 478.501 + 440.696 )) = 105.424

Corcept Therapeutics's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2020 is calculated as:

 ROC % (Q: Dec. 2020 ) = NOPAT / Average Invested Capital = Operating Income * ( 1 - Tax Rate % ) / ( (Invested Capital (Q: Sep. 2020 ) + Invested Capital (Q: Dec. 2020 )) / count ) = 122.04 * ( 1 - 15.62% ) / ( (80.337 + 105.424) / 2 ) = 102.977352 / 92.8805 = 110.87 %

where

 Invested Capital (Q: Sep. 2020 ) = Total Assets - Accounts Payable & Accrued Expense - Excess Cash = Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets + Cash, Cash Equivalents, Marketable Securities )) = 534.125 - 33.343 - ( 428.793 - max(0, 43.048 - 463.493 + 428.793 )) = 80.337

 Invested Capital (Q: Dec. 2020 ) = Total Assets - Accounts Payable & Accrued Expense - Excess Cash = Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets + Cash, Cash Equivalents, Marketable Securities )) = 571.731 - 35.3 - ( 440.696 - max(0, 47.494 - 478.501 + 440.696 )) = 105.424

Note: The Operating Income data used here is four times the quarterly (Dec. 2020) data.

* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.

Corcept Therapeutics  (NAS:CORT) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Corcept Therapeutics's WACC % is 4.87%. Corcept Therapeutics's ROC % is 107.29% (calculated using TTM income statement data). Corcept Therapeutics generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.